I am an experienced, result-oriented life science executive with a broad scientific-technical background and extensive business experience. I have a passion for developing complex technological opportunities into viable businesses with• Sustainable business models and company values• Clear goals translated into viable strategies and dynamic organisations• Defined processes and quality by designI believe in developing people, building strong teams and providing visible leadership with a strong focus on communication.I have specific experience with: • Business development: M&A and Due Diligence processes and partnering• Financing: Venture capital, IPOs and Investor Relations and non-diluting funding• R&D from discovery to clinical programs, including QA/QC, CMC and regulatory issuesScientific focus: Immunology, immune therapy, allergy, vaccines, gene therapy, recombinant proteins and viral vectors.Keywords: Life sciences, Leadership, Strategy, Business Development, Financing, IP, R&D, Quality, AI and Communication
-
Chief Executive OfficerZyneyroCopenhagen, Dk
-
Chief Executive OfficerZyneyro Nov 2024 - PresentHørsholm, Dk -
Managing DirectorScientific Innovation Management Jun 2023 - PresentA company that provides strategic and operational support for management in the life science industry. Specialises in the dynamic integration of strategy, financing, organisation, communication, and business development. The company also offers operational support for R&D, Q, due diligence, and interim management.
-
Chief Executive OfficerAmarna Therapeutics B.V. Sep 2020 - May 2023Leiden, NlAmarna Therapeutics is a privately held biotech company in Leiden in the Netherlands, that develops new gene therapies based on its unique, non-immunogenic vector platform.Major achievements- Obtained financing for the continuation of the company- Developed, re-focused, digitalized, and re-branded the organization- Initiated BD and partnering, making the company a recognized player in the Gene Therapy field -
Managing DirectorScientific Innovation Management Jan 2020 - Sep 2020A company providing strategic and operational support for life science executives and managers.S:I:M have successfully supported several companies and foundations within strategy, financing, valuation, business plans, due diligence, and interim management.
-
Chairman Of The BoardAdaptvac Oct 2017 - Jan 2020Horsholm, Zealand, DkAdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines from 2017. The company develops new vaccines based on its Virus-Like Particle (VLP) platform.Key achievements - Led the change from semi-academic entity towards a functional business unit- Established partnerships through active engagement in business development & PR- Ensured the consolidation and expansion of crucial proprietary rights -
CeoExpres2Ion Biotech Holding Ab Jun 2016 - Dec 2019ExpreS2ion Biotech Holding AB is a public Swedish company, listed on Nasdaq First North As CEO, I successfully executed the IPO at Nasdaq First North in Stockholm in 2016, followed by successful emissions in 2017, 2018, and 2019, as well as a convertible bridge loan facility in late 2019. I was managing financing, compliance (Nasdaq, Euroclear, MAR, FI etc.), reporting, IR, press releases as well as the development of an effective branding profile.Key achievements- Sucessfully executed the listing of the company at Nasdaq First North in Stockholm in three months- Execution of three additional successful emissions + a convertible bridge loan facility in three years - Enabled acquisition and development of assets securing growth and multiplying the company's value - Transformed the DK business unit from a CMO to a CDMO / biotech with a valuable pipeline
-
CeoExpres2Ion Biotechnologies Aps Apr 2016 - Dec 2019ExpreS2ion Biotechnologies ApS is a Danish CDMO/Biotech company working with development of vaccines and diagnostics. It is a fully owned subsidiary of the listed ExpreS2ion Biotech Holding AB.As the CEO, I led the management group and spearheaded overall functions of business model, strategy, financing, partnering, and media. Through this, the turnaround and transformation of a staggering CRO business into a CDRO & Biotech company was finalized in three years. This included development of new platform technology and IP, as well as partnerships and new assets providing a high value pipeline and solid growth potential. Key achievements:- Successful execution of a turnround and transformation strategy, taking the company from a CRO to an emerging CDRO/Biotech with valuable pipeline.- Secured future value growth potential and new opportunities through targeted organizational development, partnering and acquisition of new assets.
-
Svp Pre-Clinical R&DAllergopharma, Business Unit Allergy At Merck Group Nov 2011 - Feb 2016Reinbek, DeMember of the company’s executive management team reporting to the CEO. Managing 50 scientists/technicians and all R&D line managers. Responsible for the company’s preclinical R&D, including IP, M&A activities and a recombinant pilot production facility.- Established numerous cutting-edge scientific collaborations and partnerships- Identified and acquired new and innovative platform technology for allergy treatment- Managed the development and transfer of urgent new technology for QC and production -
Svp QualityAllergopharma, Business Unit Allergy At Merck Group Dec 2012 - Sep 2013Reinbek, DeGovernance of +100 employees and direct report for the directors of QA and QC. Mediated the development and implementation of new QC analytics and QA alignment to ensure compliance with new guidelines. Responsible for the direct communication with PEI and other authorities on changes, findings, and inspections.Key achievements- Implemented essential adjustments and updates to QA/QC in accordance to new guidelines- Solved urgent, critical technical issues threatening the overall company product pipeline - Successfully managed communication on critical issues with regulatory authorities (PEI/EMEA)
-
Chairman Of The BoardMinervax Mar 2010 - Oct 2013
-
Member Of The BoardVaccibody Jun 2011 - Jun 2012
-
CeoNordic Vaccine Mar 2007 - Oct 2011Dk -
Vp Of Protein Chemistry R&D, Director Of CmcPharmexa 2004 - 2007Dk -
Board Of DirectorsPharmexa 2003 - 2007Dk
-
Head Of Protein Technology, Project Manager & Senior ScientistPharmexa 1997 - 2004Dk
-
ScientistNovo Nordisk 1995 - 1997Bagsværd, Dk -
ScientistAlk-Abello 1990 - 1996Including "on site" indusstrial Ph.D. in collaboration with DTU / ATV
Steen Klysner Education Details
-
Dtu - Technical University Of DenmarkImmunology & Protein Chemistry -
Danish Academy Of Technical SciencesIntellectual Property Rights And Project Management
-
Københavns Universitet - University Of CopenhagenBiochemistry
-
Københavns Universitet - University Of CopenhagenSports
Frequently Asked Questions about Steen Klysner
What company does Steen Klysner work for?
Steen Klysner works for Zyneyro
What is Steen Klysner's role at the current company?
Steen Klysner's current role is Chief Executive Officer.
What schools did Steen Klysner attend?
Steen Klysner attended Dtu - Technical University Of Denmark, Danish Academy Of Technical Sciences, Københavns Universitet - University Of Copenhagen, Københavns Universitet - University Of Copenhagen.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial